Scynexis is a company engaged in drug discovery, development, and manufacturing projects in various areas. The company also provides contract research solutions including medicinal chemistry, discovery biology, ADMET-PK, bioanalysis and analytical chemistry, process chemistry, and cGMP manufacturing. Its lead compound, Ibrexafungerp (formerly SCY-078), helps with the treatment of multiple serious fungal infections, including vulvovaginal candidiasis, invasive candidiasis, invasive aspergillosis, and refractory invasive fungal infections.